Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Clin Proteomics ; 21(1): 35, 2024 May 19.
Article in English | MEDLINE | ID: mdl-38764042

ABSTRACT

BACKGROUND: Currently, no effective measures are available to predict the curative efficacy of small-cell lung cancer (SCLC) chemotherapy. We expect to develop a method for effectively predicting the SCLC chemotherapy efficacy and prognosis in clinical practice in order to offer more pertinent therapeutic protocols for individual patients. METHODS: We adopted matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and ClinPro Tools system to detect serum samples from 154 SCLC patients with different curative efficacy of standard chemotherapy and analyze the different peptides/proteins of SCLC patients to discover predictive tumor markers related to chemotherapy efficacy. Ten peptide/protein peaks were significantly different in the two groups. RESULTS: A genetic algorithm model consisting of four peptides/proteins was developed from the training group to separate patients with different chemotherapy efficacies. Among them, three peptides/proteins (m/z 3323.35, 6649.03 and 6451.08) showed high expression in the disease progression group, whereas the peptide/protein at m/z 4283.18 was highly expressed in the disease response group. The classifier exhibited an accuracy of 91.4% (53/58) in the validation group. The survival analysis showed that the median progression-free survival (PFS) of 30 SCLC patients in disease response group was 9.0 months; in 28 cases in disease progression group, the median PFS was 3.0 months, a statistically significant difference (χ2 = 46.98, P < 0.001). The median overall survival (OS) of the two groups was 13.0 months and 7.0 months, a statistically significant difference (χ2 = 40.64, P < 0.001). CONCLUSIONS: These peptides/proteins may be used as potential biological markers for prediction of the curative efficacy and prognosis for SCLC patients treated with standard regimen chemotherapy.

2.
J Environ Manage ; 360: 121153, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38772234

ABSTRACT

Strategic coordination between urbanization and carbon emission efficiency (CEE) is vital for promoting low-carbon urbanization and sustainable urban planning. In order to assess the coupled coordination degree (CCD) of urbanization and CEE and investigate the factors influencing the CCD, this research employs the Super slacks-based measure (SBM) model, the coupled coordination degree model (CCDM), and the Tobit model. Four key findings emerge from the analysis of the temporal and spatial evolution traits of the CCD based on data from 106 nations worldwide between 2005 and 2020. (1) The global CEE shows a significant downward trend, and the spatial disparity is unambiguous. high CEE countries hang in the north and west of Europe, while those in Asia, Africa and the east of Europe have lower CEE. (2) The combined urbanization level and demographic, economic and social urbanization are all on an upward trend. Singapore has the greatest degree of urbanization overall globally. (3) The CCD of urbanization and CEE shows a fluctuating upward trend, with particularly strong changes in 2018-2020. 2017 and 2018 are the years with better global coupling coordination status. During the study period, the CCD results of countries are mostly uncoordinated and low coordination, and the CCD of the United States, China, India and Japan is in the front. (4) The effect of urban electrification rate on the CCD is positive; the effect of foreign trade and net inflow of foreign direct investment is negative; while energy structure and industrial structure have no significant effect. A number of policy proposals are put forth in light of the outcomes of the research to enhance the coordination.


Subject(s)
Carbon , Urbanization
3.
Front Immunol ; 15: 1371559, 2024.
Article in English | MEDLINE | ID: mdl-38576625

ABSTRACT

Anti-PD-(L)1 therapy has shown great efficacy in some patients with cancer. However, a significant proportion of patients with cancer do not respond to it. Another unmet clinical need for anti-PD-(L)1 therapy is the dynamic monitoring of treatment effects. Therefore, identifying biomarkers that can stratify potential responders before PD-(L)1 treatment and timely monitoring of the efficacy of PD-(L)1 treatment are crucial in the clinical setting. The identification of biomarkers by liquid biopsy has attracted considerable attention. Among the identified biomarkers, circulating T cells are one of the most promising because of their indispensable contribution to anti-PD-(L)1 therapy. The present review aimed to thoroughly explore the potential of circulating T cells as biomarkers of anti-PD-(L)1 therapy and its advantages and limitations.


Subject(s)
Neoplasms , T-Lymphocytes , Humans , Biomarkers , Immunotherapy , Neoplasms/drug therapy
4.
Exp Hematol Oncol ; 13(1): 48, 2024 May 09.
Article in English | MEDLINE | ID: mdl-38725070

ABSTRACT

BACKGROUND: Cancer is the leading cause of death among older adults. Although the integration of immunotherapy has revolutionized the therapeutic landscape of cancer, the complex interactions between age and immunotherapy efficacy remain incompletely defined. Here, we aimed to elucidate the relationship between aging and immunotherapy resistance. METHODS: Flow cytometry was performed to evaluate the infiltration of immune cells in the tumor microenvironment (TME). In vivo T cell proliferation, cytotoxicity and migration assays were performed to evaluate the antitumor capacity of tumor antigen-specific CD8+ T cells in mice. Real-time quantitative PCR (qPCR) was used to investigate the expression of IFN-γ-associated gene and natural killer (NK)-associated chemokine. Adoptive NK cell transfer was adopted to evaluate the effects of NK cells from young mice in overcoming the immunotherapy resistance of aged mice. RESULTS: We found that elderly patients with advanced non-small cell lung cancer (aNSCLC) aged ≥ 75 years exhibited poorer progression-free survival (PFS), overall survival (OS) and a lower clinical response rate after immunotherapy. Mechanistically, we showed that the infiltration of NK cells was significantly reduced in aged mice compared to younger mice. Furthermore, the aged NK cells could also suppress the activation of tumor antigen-specific CD8+ T cells by inhibiting the recruitment and activation of CD103+ dendritic cells (DCs). Adoptive transfer of NK cells from young mice to aged mice promoted TME remodeling, and reversed immunotherapy resistance. CONCLUSION: Our findings revealed the decreased sensitivity of elderly patients to immunotherapy, as well as in aged mice. This may be attributed to the reduction of NK cells in aged mice, which inhibits CD103+ DCs recruitment and its CD86 expression and ultimately leads to immunotherapy resistance.

SELECTION OF CITATIONS
SEARCH DETAIL